Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 SECRETAI 04 JUL

## **LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name		
Larson Dodd Stewart & Myrick, LLC		
2. Address		
122 C Street, NW, Suite 500		
3. Principal Place of Business (if different from line 2)		
Washington DC/20001		
City: State/zip	(or Country)	
4. Contact Name Telephone	E-mail (optional) 5. Senate ID #	•
Dave Larson (202) 628-3750		
7. Client Name  Self		
Pharmaceutical Research & Manufacturers of America		)2
9. Check if this filing amends a previously filed version of this report ☐  10. Check if this is a Termination Report ☐ ☐ Termination Date		
12. Lobbying Firms	13. Organizations	
12. Dobbynig i mits		
INCOME relating to lobbying activities for this reporting period was:	<b>EXPENSES</b> relating to lobbying activities for this reperiod were:	apoi
Less than \$10,000 🗆	Less than \$10,000 🗖	
\$10,000 or more	\$10,000 or more	0.00
Income (nearest \$20,000)	Expenses (nearest \$2	0,00
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicat accounting method. See instructions for description of	
	☐ Method A. Reporting amounts using LDA def	init
	☐ Method B. Reporting amounts under section € Internal Revenue Code	5033
	☐ Method C. Reporting amounts under section I Internal Revenue Code	162(
MNZ	Date 7/1/04	

Signature —		
	Dave Larson, Member	
Printed Name and Title -		
LD-2 (REV. 4/03)		PAGE 1

Registrant Name Larson Dodd Stewart & Myrick, LLC	lient Name Pharmaceutical Research & Manufacturers of A
LOBBYING ACTIVITY. Select as many codes as engaged in lobbying on behalf of the client during the information as requested. Attach additional page(s) as no 15. General issue area code (one per page)	necessary to reflect the general issue areas in which the reporting period. Using a separate page for each contended.
16. Specific lobbying issues	
Medicare Reform/Rx Drug Coverage - Medicare Issues	
17. House(s) of Congress and Federal agencies contacte	d Check if None
United States Senate United States House of Representatives Department of Health and Human Services Executive Office of the President  18. Name of each individual who acted as a lobbyist in	this issue area
	1
Name  Dave Larson	Covered Official Position (if applicable)  Health Policy Advisor, Senator Bill Frist (R-TN)
Quin Dodd	LD, Senator Kay Baily Hutchison (R-TX)
Tim Stewart	Chief of Staff, House Resources Committee
Chris Myrick	
19. Interest of each foreign entity in the specific issues list	ted on line 16 above
Signature MMA	Date

Dave Latoutt, Mettibet

Form LD-2 (Rec. 4/03)

Page 2

Registrant Name Larson Dodd Stewart & Myrick, LLC Clie	ent Name Pharmaceutical Research & Manufacturers of A
LOBBYING ACTIVITY. Select as many codes as neengaged in lobbying on behalf of the client during the reinformation as requested. Attach additional page(s) as need 15. General issue area code HCR (one per page)	ecessary to reflect the general issue areas in which the porting period. Using a separate page for each coded.
16. Specific lobbying issues  FDA Issues  Drug Patent Issues	
17. House(s) of Congress and Federal agencies contacted  United States Senate United States House of Representatives Department of Health and Human Services Executive Office of the President	☐ Check if None
18. Name of each individual who acted as a lobbyist in th	is issue area
Name Dave Larson	Covered Official Position (if applicable)  Health Policy Advisor, Senator Bill Frist (R-TN)
Quin Dodd	LD, Senator Kay Baily Hutchison (R-TX)
Tim Stewart	Chief of Staff, House Resources Committee
Chris Myrick	
19. Interest of each foreign entity in the specific issues listed	d on line 16 above
Signature MMA	Date

Dave Laison, Member

Form LD-2 (Rec. 4/03)

Page 3